Statement by HINJ President and Chief Executive Officer Dean J. Paranicas in Response to Governor Murphy’s Drug Pricing Proposal
Trenton, February 14, 2022 ― “While we await the opportunity to review the actual bills that Governor Murphy proposed today, we look forward to working with the Administration and Legislature to broaden patient access to innovative medicines and therapies to improve patient outcomes and their quality of life. It is critical that this effort includes […]
Big Pharma Is to Blame for Drug Prices? Addressing Claims Shows That’s Not the Case
An op-ed by Dean J. Paranicas, HINJ President and Chief Executive Officer New Jersey’s research-based biopharmaceutical industry is constantly developing new cures and treatments that benefit New Jerseyans and patients worldwide. Over the past two years, we all have witnessed firsthand the industry’s remarkable and rapid response to identifying, treating and inoculating against COVID-19 with innovative […]
More Than Half of Spending on Brand Medicines Goes to PBMs, the Supply Chain, Other Entities – Not to Drug Companies
$350 billion goes to middlemen Trenton, January 11, 2022 ― An update to an important study demonstrates that pharmacy benefit managers (PBMs) and other middlemen in the pharmaceutical supply chain – not the drug companies – now receive more than half of the money spent on brand medicines. This represents money that instead could be […]
Help Scientists Combat the Next Global Health Crisis
An op-ed by Dean J. Paranicas, HINJ President and Chief Executive Officer and Christopher P. Molineaux, President and Chief Executive Officer of Life Sciences Pennsylvania December 26, 2021 – Nature is always finding fresh ways to attack human health. As America and the world combat the most serious global health crisis in a century, it’s […]
Edison Patent Awards Tribute Video
Leaders of three HINJ member companies and HINJ CEO named to ROI-NJ Influencers: Healthcare 2021 list
Kenneth Frazier, executive chairman, and Robert Davis, chief executive officer of Merck; Alex Gorsky, chairman and chief executive officer, and Joaquin Duato, incoming chief executive officer of Johnson & Johnson; Tom Polen, chairman and chief executive officer of BD: and Dean J. Paranicas, president and chief executive officer of HINJ, have been named to the […]
Regional Business Leaders Warn of Tremendous Loss of Jobs, Economic Output from H. R. 3
This legislation poses the danger of decimating the workforces and economies of Delaware, New Jersey and Pennsylvania. August 30, 2021 ― Thirty business leaders in Delaware, New Jersey and Pennsylvania have joined a letter to the three states’ Congressional Delegations voicing their opposition to a drug-pricing bill currently before the House of Representatives, H. […]
HINJ Statement on President Biden’s Drug Pricing Announcement
This legislation poses the danger of decimating New Jersey’s workforce and economy. Trenton, August 12, 2021 ― HealthCare Institute of New Jersey (HINJ) President and Chief Executive Officer Dean J. Paranicas today issued the following statement about President Biden’s drug pricing announcement: “The HealthCare Institute of New Jersey (HINJ) opposes President Biden’s proposal to effectively […]
HINJ Honors NJMEP – Pro Action Education Network with STEM Education Award
HINJ recognized the New Jersey Manufacturing Extension Program – Pro Action Education Network (NJMEP) with its HINJ Excellence in STEM Education Award at the NJMEP’s South Jersey “State of the State of Manufacturing” conference on July 30. HINJ honored the NJMEP – Pro Action Education Network for its outstanding work and leadership in preparing students […]
HINJ Honors Senator Loretta Weinberg with Bob Franks Public Service Award
The following press release was issued on May 26 by the Senate Democrat Office on behalf of Senator Weinberg. HINJ Recognizes Senator Loretta Weinberg with the Bob Franks Public Service Award TRENTON – Senate Majority Leader Loretta Weinberg, a long-time advocate for access to quality health care for all, and a believer in […]